Status:
UNKNOWN
A Study of DC-CIK to Treat Hepatocellular Carcinoma
Lead Sponsor:
Guangxi Medical University
Conditions:
Hepatocellular Carcinoma (HCC)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate the efficacy of Dendritic and Cytokine-induced Killer Cells (DC-CIK) for hepatocellular carcinoma (HCC).
Detailed Description
About 60 patients with HCC, who had received complete resection or TACE and got Complete remission (CR) or partial response (PR), will be randomly divided into group A (receive DC-CIK treatment) or gr...
Eligibility Criteria
Inclusion
- Male or female patients \> 18 years of age;
- Hepatocellular carcinoma with histological or imaging and AFP diagnose, and had received complete resection or TACE and got CR or PR by imaging studies;
- Patients who have a life expectancy of at least 12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1;
- The bone marrow functioned normally (WBC \> 4.0×109/L, Hb \> 120 g/L, PLT \> 100×109/L);
- The ECG results were normal, and the liver and kidney were functional.
Exclusion
- Patients who had distant metastases;
- Patients with uncontrolled infection; underlying disease that was severe or life-threatening;
- Patients who were pregnant or lactating;
- ECOG perform status ≥ 2;
- Patients who are suffering from auto immune diseases or patients who need to accept glucocorticoid treatment.
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01821482
Start Date
May 1 2013
End Date
May 1 2018
Last Update
April 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The first Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China, 530000